Endologix, Inc.
ELGX, developer and marketer of innovative treatments for aortic
disorders, announced today that it has achieved $10 million in trailing twelve
month international sales of the Nellix® EndoVascular Aneurysm Sealing System,
triggering a milestone payment to the former Nellix, Inc. stockholders, in the
form of 2,666,555 shares of Endologix common stock.
John McDermott, Chairman and Chief Executive Officer for Endologix, said, "We
are pleased to have reached this significant revenue milestone during the
controlled market introduction of Nellix. The Nellix system continues to
generate positive physician feedback including procedure predictability and
the capability to treat a wide range of AAA anatomies. This feedback and early
market adoption gives us continued confidence in the potential of Nellix to
become the leading global treatment of AAA."
Based on the Company's 2010 acquisition agreement for Nellix, Inc., the
revenue milestone triggered a $20 million payment in Endologix common stock to
former Nellix, Inc. stockholders. The stock price used to calculate the share
payment is subject to a floor of $3.50 and a ceiling of $7.50. Accordingly,
because Endologix's stock price is currently above the $7.50 ceiling, the
Company will issue 2,666,555 shares by the end of June 2014.
Nellix has obtained CE Mark and is currently undergoing a U.S. Investigational
Device Exemption (IDE) trial to establish clinical evidence for U.S. Food and
Drug Administration (FDA) approval. The U.S. study, EVAS FORWARD-IDE is
approved to enroll 180 patients at up to 30 sites in the U.S., Canada and
Europe. The EVAS FORWARD Global Registry is planned to include 300 patients
enrolled in up to 30 international centers. Nellix has not been approved for
marketing or commercial sale in the US.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in